Durable response of cutaneous squamous cell carcinoma following high-dose peri-lesional injections of Viscum album extracts – A case report

Durable response of cutaneous squamous cell carcinoma following high-dose peri-lesional injections of Viscum album extracts – A case report

Cutaneous squamous cell carcinoma (CSCC) is a common locally invasive skin cancer which rarely metastasises. First-line treatment is surgical excision, which is curative in most cases. Viscum album extract (VAE) is a widely used herbal cancer treatment with cytotoxic, apoptogenic and immunological e...

Full description

Saved in:
Bibliographic Details
Published in:Phytomedicine (Stuttgart) Vol. 20; no. 3-4; pp. 324 - 327
Main Authors: Werthmann, Paul Georg, Sträter, Gregor, Friesland, Hedda, Kienle, Gunver Sophia
Format: Journal Article
Language:English
Published: Germany Elsevier GmbH 15-02-2013
Urban & Fischer Verlag
Subjects:
Aged
Carcinoma, Squamous Cell - drug therapy
Care and treatment
Case report
Case studies
Cutaneous squamous cell carcinoma
Facial Neoplasms - drug therapy
Health aspects
Humans
Injections
Male
Medicine, Botanic
Medicine, Herbal
Mistletoe
Phytotherapy
Plant Extracts - administration & dosage
Risk factors
Skin
Skin cancer
Squamous cell carcinoma
Viscum
Viscum album
Germany
Case report
Cutaneous squamous cell carcinoma
Mistletoe
Viscum
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous squamous cell carcinoma (CSCC) is a common locally invasive skin cancer which rarely metastasises. First-line treatment is surgical excision, which is curative in most cases. Viscum album extract (VAE) is a widely used herbal cancer treatment with cytotoxic, apoptogenic and immunological effects, but has not been investigated in CSCC. A 78-year-old patient with histologically diagnosed CSCC refused surgical excision and was treated with peri-lesional high-dose VAE. After 10 months of treatment the CSCC had disappeared clinically. The patient has been recurrence-free for 4 years. The presented case shows clinical response of a CSCC to high-dose peri-lesional VAE injections. Further research on VAE in CSCC is warranted.
Bibliography:http://dx.doi.org/10.1016/j.phymed.2012.11.001
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0944-7113
1618-095X
DOI:10.1016/j.phymed.2012.11.001